GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Immuneering Corporation
Shares of Immuneering, a biotech company using a computational platform for drug discovery, are a bet on its scientific approach. The price trajectory depends on news from preclinical and early clinical studies that could confirm the potential of its technology.
Share prices of companies in the market segment - Oncology targeted therapy
Immuneering Corporation is a biopharmaceutical company using a bioinformatics platform to develop next-generation targeted cancer therapies. We've classified it in the "Oncology Targeted Therapy" segment. The chart below illustrates the overall dynamics of this high-tech sector, where data and AI are accelerating drug discovery.
Broad Market Index - GURU.Markets
Immuneering Corporation is an oncology company that uses its platform for mapping disease signaling pathways to develop targeted therapies. As a component of the GURU.Markets index, it represents the biotech sector. The chart below represents the entire market. See how Immuneering shares compare to the overall trend.
Change in the price of a company, segment, and market as a whole per day
IMRX - Daily change in the company's share price Immuneering Corporation
For Immuneering, an oncology company, change_co is a measure of the sector's inherently high volatility. Each daily change reflects sensitivity to clinical trial news. This metric isn't just noise, but a critical component of the models at System.GURU.Markets that assess risk in innovative medicine.
Daily change in the price of a set of shares in a market segment - Oncology targeted therapy
Immuneering Corporation is an oncology company. This chart demonstrates the extreme volatility of the biotech sector. Comparison with IMRX's performance, which depends on clinical trial results, helps to assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Immuneering is a biopharmaceutical company developing cancer treatments. Oncology is a highly volatile sector driven by clinical trial results. The chart below shows the average fluctuations in this industry, providing context for evaluating Immuneering stock.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Immuneering Corporation
Immuneering Corporation's year-over-year performance is a story of bioinformatics being applied to the development of new cancer drugs. Its 12-month market cap depends on progress in early clinical trials, where the company must prove that its computational approach can truly lead to the development of effective targeted therapies.
Annual dynamics of market capitalization of the market segment - Oncology targeted therapy
Immuneering Corporation uses its bioinformatics platform to develop targeted cancer treatments. Its stock performance is entirely dependent on clinical trial results. The chart reflects the high risks and potential for breakthroughs typical of the biotech sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Immuneering is a clinical-stage biotech whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of new drug trials. The company's chart exists in a world of its own, where the main events are data releases.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Immuneering Corporation
The performance of Immuneering, a biopharmaceutical company, is speculative. Monthly fluctuations on the chart reflect not revenue, but rather news about the progress of clinical trials of its oncology drugs based on its unique platform, which determines its future.
Monthly dynamics of market capitalization of the market segment - Oncology targeted therapy
Immuneering Corporation uses a bioinformatics platform to develop targeted cancer treatments. The company aims to create drugs that overcome resistance to therapy. The oncology sector's performance reflects overall investor interest in this field, providing a backdrop for evaluating Immuneering's innovative, science-intensive approach.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Immuneering Corporation uses artificial intelligence to develop cancer drugs. Like many biotech companies, its shares are highly volatile and do not follow the market. Price movements are a reaction to research data and partnership news. The chart demonstrates how scientific expectations outweigh general economic factors.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Immuneering Corporation
Immuneering Corporation uses AI to develop cancer drugs, placing it at the intersection of biotech and tech. Its weekly stock performance reflects both progress in clinical trials and overall investor sentiment regarding artificial intelligence platforms in pharmaceuticals.
Weekly dynamics of market capitalization of the market segment - Oncology targeted therapy
Biotech companies using AI in drug development, like Immuneering, are benefiting from the general hype surrounding artificial intelligence. The chart below shows the dynamics of this segment. It allows us to assess how successfully Immuneering is applying its platform to oncology compared to other companies working at the intersection of biotech and AI.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Immuneering Corporation uses an artificial intelligence platform to develop oncology drugs. It's a combination of biotech and AI. The chart shows how the company's shares react to sentiment in both of these hyped industries, which can lead to high volatility, different from the market.
Market capitalization of the company, segment and market as a whole
IMRX - Market capitalization of the company Immuneering Corporation
Immuneering Corporation's market capitalization chart reflects investors' bets on its platform, which uses bioinformatics to develop targeted oncology drugs. Its dynamics reflect the market's belief that its computational approach will lead to more effective drug development. Its value is an estimate of the potential of its early-stage clinical developments.
IMRX - Share of the company's market capitalization Immuneering Corporation within the market segment - Oncology targeted therapy
Immuneering Corporation uses an AI-powered platform to develop targeted oncology drugs. Its market capitalization within its segment reflects investors' bets on its technological approach. The company's market share reflects the market's belief that its methods will enable faster and more effective drug development than traditional approaches.
Market capitalization of the market segment - Oncology targeted therapy
The chart below shows the overall market capitalization of the biotech sector focused on targeted cancer therapy. For Immuneering, which uses AI for drug discovery, this line represents the market's size. Its growth reflects investors' belief that new technologies like the company's platform can accelerate and reduce the cost of developing breakthrough cancer treatments.
Market capitalization of all companies included in a broad market index - GURU.Markets
Immuneering Corporation uses bioinformatics to develop targeted cancer drugs. Its market capitalization reflects its "smart" approach to drug development. Overall, this represents the share of technologies at the intersection of biology and big data in pharmaceuticals.
Book value capitalization of the company, segment and market as a whole
IMRX - Book value capitalization of the company Immuneering Corporation
Immuneering Corporation uses bioinformatics to develop cancer drugs. Its book value is its financial and intellectual capital. It consists of cash for R&D and the value of its proprietary platform. How has this capital changed as development progressed? The chart below shows this story.
IMRX - Share of the company's book capitalization Immuneering Corporation within the market segment - Oncology targeted therapy
Immuneering Corporation uses bioinformatics to develop drugs, but its work also requires physical assets. These include computing clusters for modeling and in-house laboratories for validating targeted oncology drugs. The chart shows the company's share of the hybrid IT and R&D infrastructure of modern biotech.
Market segment balance sheet capitalization - Oncology targeted therapy
Immuneering Corporation, a biopharmaceutical company, operates a lightweight business. It uses its AI platform for drug discovery, which requires computing power rather than large laboratories. The BCap_Seg chart for the biotech sector will show the contrast between these "digital" and traditional companies.
Book value of all companies included in the broad market index - GURU.Markets
Immuneering's capital isn't a laboratory in the traditional sense, but a powerful computing platform for modeling cellular signaling pathways and drug development. Its assets are primarily technology and data. The chart shows how this "digital" R&D asset compares to biotech companies with "wet" labs.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Immuneering Corporation
Immuneering's balance sheet isn't its laboratories, but its computational drug modeling platform. Its entire market value is a premium for its "digital" approach to R&D. Its pipeline is a bet that its algorithms will be able to discover new drugs faster and more cost-effectively than traditional methods.
Market to book capitalization ratio in a market segment - Oncology targeted therapy
Immuneering Corporation uses bioinformatics to develop targeted cancer drugs. Its high valuation on this chart reflects its unique platform, which can accelerate drug discovery, based on its scientific potential rather than its tangible assets.
Market to book capitalization ratio for the market as a whole
Immuneering Corporation uses an AI-powered platform to develop cancer drugs. Its value lies in its technology platform and pipeline. This results in a market valuation that significantly exceeds its book value, reflecting investor confidence in the potential of its innovative approach.
Debts of the company, segment and market as a whole
IMRX - Company debts Immuneering Corporation
Immuneering Corporation, a clinical-stage biopharmaceutical company, is using its platform to develop targeted cancer therapies. All capital is directed toward funding expensive R&D. This chart shows how the company manages its resources to advance its scientific developments through the complex and lengthy clinical trial process.
Market segment debts - Oncology targeted therapy
Immuneering Corporation is a clinical-stage biotech company using a platform to develop cancer drugs. The financial model for such companies is based on burning capital on R&D in anticipation of future success. Debt is rare here. This chart will likely show a near-zero level of borrowing, which is typical for the industry.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Immuneering Corporation
Immuneering Corporation uses AI to develop oncology drugs. This requires significant investment in technology and clinical research. This chart shows the company's reliance on debt to fund its innovation efforts. It reflects the financial risk inherent in biotech startups on the path to developing their first commercial product.
Market segment debt to market segment book capitalization - Oncology targeted therapy
Immuneering Corporation uses an artificial intelligence platform to develop new cancer drugs. The combination of IT and biotechnology requires dual investments—in software and labs. The chart shows how the sector uses debt to fund cutting-edge R&D, providing context for assessing Immuneering's capital-intensive strategy.
Debt to book value of all companies in the market
Immuneering Corporation uses bioinformatics for drug development, which has the potential to reduce R&D costs but still requires investment. This chart shows the overall market leverage, allowing one to assess whether the company's technological approach allows it to maintain a healthier capital structure than traditional biotech companies.
P/E of the company, segment and market as a whole
P/E - Immuneering Corporation
Immuneering Corporation is a biotechnology company using a bioinformatics platform to develop next-generation targeted therapies for cancer treatment. This chart shows how investors evaluate its technological approach. This assessment is based on the potential of its platform to discover new targets and create effective drugs.
P/E of the market segment - Oncology targeted therapy
Immuneering uses AI to develop cancer drugs. This chart shows the average valuation for the biotech sector. It emphasizes that Immuneering is valued not by profit, but by the potential of its technology platform to accelerate and reduce the cost of drug development, which the market may value at a significant premium to the average.
P/E of the market as a whole
Immuneering Corporation is a biopharmaceutical company using a bioinformatics platform to develop small-molecule drugs targeting cancer cell signaling pathways. This chart reflects overall investor risk appetite. It helps understand whether IMRX's valuation is based on faith in its technology platform or is moving in line with overall sector sentiment.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Immuneering Corporation
Immuneering Corporation uses an artificial intelligence platform to develop targeted cancer drugs. Future profits depend on the ability of its technology to find effective drug targets. This chart shows market expectations for the success of its computational approach in developing next-generation oncology drugs.
%20P%2FE%20Immuneering%20Corporation&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Immuneering-Corporation&v=1772513885283 "Chart of the company's future (projected) P/E Immuneering Corporation")
Future (projected) P/E of the market segment - Oncology targeted therapy
Immuneering Corporation uses an AI-based platform to develop targeted cancer drugs that target cell signaling pathways. The data here reflects analysts' collective bets on the success of its innovative drug discovery approach. It's a barometer of expectations that its technologies will accelerate the development of effective therapies.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Oncology%20targeted%20therapy&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Oncology-targeted-therapy&v=1772513885290 "Future (projected) P/E graph of the market segment - Oncology targeted therapy")
Future (projected) P/E of the market as a whole
Immuneering Corporation uses bioinformatics to develop targeted cancer drugs. Their approach is based on big data analysis. This sentiment chart shows how much investor confidence there is in companies combining biotechnology and artificial intelligence to create next-generation drugs.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772513885320 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Immuneering Corporation
Immuneering Corporation uses an AI-based platform to develop targeted cancer treatments. This chart reflects the financial side of biopharmaceutical innovation. It shows R&D investments, where every dollar is a bet that their computational approach will accelerate drug discovery.
Profit of companies in the market segment - Oncology targeted therapy
Immuneering Corporation is a biopharmaceutical company using a platform approach to develop targeted therapies in oncology. The company is in the clinical stage, and its financial history is one of investment in research. The potential success of its drugs could significantly contribute to the sector's profitability, demonstrating the biotech model's innovation-driven approach.
Overall market profit
Immuneering Corporation is a biotech company using a bioinformatics platform to develop cancer drugs. Its success depends on scientific breakthroughs. While there's no direct correlation with the economic cycle, the overall market conditions, which are influenced by this cycle, determine the availability of capital. For early-stage companies, this is a critical factor for survival and growth.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Immuneering Corporation
Immuneering Corporation uses an artificial intelligence platform to develop new oncology drugs. This chart reflects analysts' speculative earnings expectations. The forecast depends on the platform's ability to successfully identify promising candidates and subsequent progress in clinical trials.
%20profit%20of%20the%20company%20Immuneering%20Corporation&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Immuneering-Corporation&v=1772513885455 "Graph of future (projected) profit of the company Immuneering Corporation")
Future (predicted) profit of companies in the market segment - Oncology targeted therapy
Immuneering Corporation uses an AI-based platform to develop next-generation targeted drugs for cancer treatment. Revenue forecasts for the oncology sector, shown in the graph, demonstrate the overall market potential. This chart helps assess how Immuneering's technology can accelerate the discovery and development of effective drugs.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Oncology%20targeted%20therapy&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Oncology-targeted-therapy&v=1772513885493 "Graph of future (predicted) profits of companies in a market segment - Oncology targeted therapy")
Future (predicted) profit of the market as a whole
Immuneering Corporation is a biopharmaceutical company using its platform to develop targeted cancer therapies. Like other early-stage companies, it relies on external funding. The overall economic climate, illustrated in this chart, influences investor willingness to invest in long-term, risky research projects.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772513885529 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Immuneering Corporation
Immuneering Corporation uses an AI-based platform to develop next-generation targeted cancer therapies. Being in the early clinical stage, the company may not generate revenue. This chart shows how investors view its technology platform and the potential of its unique approach to drug discovery.
P/S market segment - Oncology targeted therapy
Immuneering Corporation is a biopharmaceutical company using a bioinformatics platform to develop targeted cancer drugs. This chart shows the average revenue estimate in the biotech sector. It helps understand how highly investors value the company's technology platform and its ability to discover new drug targets.
P/S of the market as a whole
Immuneering Corporation uses a bioinformatics platform to develop targeted cancer therapies. The company's approach is aimed at overcoming drug resistance. Future revenue depends on the success of clinical trials. This chart provides context for market valuations for companies with real revenues, against which biotech companies are analyzed.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Immuneering Corporation
Immuneering Corporation uses an AI-based platform to develop targeted cancer drugs. This chart reflects investors' high estimates of its potential future revenue. This valuation is a bet on the ability of its technology platform to accelerate the discovery and development of new drugs.
%20P%2FS%20Immuneering%20Corporation&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Immuneering-Corporation&v=1772513885634 "The graph of the company's future (projected) P/S Immuneering Corporation")
Future (projected) P/S of the market segment - Oncology targeted therapy
Immuneering Corporation is a biopharmaceutical company using a bioinformatics platform to develop targeted cancer therapies. This chart compares market expectations for its future revenue with those of its peers. This valuation reflects investor confidence in its technological approach to discovering new drug targets and the potential of its clinical programs.
%20P%2FS%20market%20segment%20graph%20-%20Oncology%20targeted%20therapy&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Oncology-targeted-therapy&v=1772513885645 "Future (projected) P/S market segment graph - Oncology targeted therapy")
Future (projected) P/S of the market as a whole
Immuneering Corporation is a clinical-stage biotechnology company using a bioinformatics platform to develop targeted cancer therapies. Its value is determined by the potential of its scientific developments. This chart of overall market expectations for Immuneering is merely a backdrop; its real drivers are its successful clinical data.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772513885668 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Immuneering Corporation
This chart visualizes the revenue of Immuneering Corporation, a clinical-stage oncology company. It uses an AI-based platform to develop targeted therapies. The lack of sales revenue is typical for this stage of development. Any revenue is likely from partnerships, and its primary value lies in its scientific potential.
Sales of companies in the market segment - Oncology targeted therapy
Immuneering Corporation uses an AI-based platform to develop a new generation of targeted cancer therapies that overcome drug resistance. This chart shows revenue in the targeted oncotherapy sector. It reflects the race to create smarter drugs, and Immuneering's approach is aimed at solving one of the most challenging problems in oncology.
Overall market sales
Immuneering Corporation uses a bioinformatics platform to develop targeted cancer drugs. The company's success depends on its scientific achievements. The overall economic situation, shown in this chart, influences the overall investment climate in the biotech sector, which affects Immuneering's ability to fund its expensive research.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Immuneering Corporation
Immuneering Corporation is a clinical-stage oncology company using a bioinformatics platform to develop targeted therapies. This revenue projection chart is entirely speculative. Its dynamics reflect analysts' confidence in the potential of its scientific developments and the likelihood of its candidates successfully completing clinical trials.
%20sales%20of%20the%20company%20Immuneering%20Corporation&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Immuneering-Corporation&v=1772513885812 "Schedule of future (projected) sales of the company Immuneering Corporation")
Future (projected) sales of companies in the market segment - Oncology targeted therapy
Immuneering Corporation uses a bioinformatics platform to develop next-generation targeted cancer therapies. Their approach aims to identify and target vulnerabilities in cancer cell signaling pathways. This chart shows projected revenue for the targeted cancer therapy sector, reflecting the trend toward personalized medicine in oncology.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Oncology%20targeted%20therapy&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Oncology-targeted-therapy&v=1772513885893 "Schedule of future (projected) sales of companies in the market segment - Oncology targeted therapy")
Future (projected) sales of the market as a whole
Immuneering Corporation uses an artificial intelligence platform to develop targeted oncology drugs. Its future depends on research success. The overall economic situation and positive market forecasts are important for attracting venture capital and partnerships with major pharmaceutical companies that fund such innovative developments.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772513885957 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Immuneering Corporation
Immuneering Corporation uses an artificial intelligence platform to discover and develop new oncology drugs. Being in the research phase, the company has no revenue. This chart visualizes its scientific ambitions, reflecting the volume of R&D investment. This is a bet that this technology will enable faster and more effective drug development in the future.
Market segment marginality - Oncology targeted therapy
Immuneering Corporation is a biopharmaceutical company using a bioinformatics platform to develop targeted drugs for cancer treatment. This chart compares its operational efficiency with other biotech companies. Its competitive advantage may be due to the effectiveness of its platform in identifying promising candidates.
Market marginality as a whole
Immuneering Corporation uses a bioinformatics platform to develop targeted cancer drugs. Like other early-stage biotech companies, its success is not dependent on the general economic cycles shown in this chart. Clinical trial data and the ability of its platform to create effective treatments are key.
Employees in the company, segment and market as a whole
Number of employees in the company Immuneering Corporation
Immuneering Corporation uses its bioinformatics platform to develop targeted cancer drugs. This chart shows its small but growing team of scientists and data scientists. This growth is a direct indicator of investment in R&D and progress in advancing its drug candidates into clinical trials.
Share of the company's employees Immuneering Corporation within the market segment - Oncology targeted therapy
Immuneering Corporation uses a computational biology platform to accelerate cancer drug development. Its approach requires a small but elite team of bioinformatics and oncology specialists. This chart highlights its technology model: its minimal staff reflects its focus on artificial intelligence and data, rather than traditional laboratory methods.
Number of employees in the market segment - Oncology targeted therapy
Immuneering Corporation is using its bioinformatics platform to develop targeted cancer treatments. This graph illustrates how modern biotech combines IT and biology. The growing number of computational biologists and traditional scientists reflects advances in the application of artificial intelligence to discover new drug targets.
Number of employees in the market as a whole
Immuneering Corporation uses an artificial intelligence platform to develop oncology drugs. Its team's growth reflects the convergence of biotechnology and IT. This employment graph shows how new professions are emerging at the intersection of sciences, and how such companies, as part of the high-tech sector, can be a leading indicator of the labor market.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Immuneering Corporation (IMRX)
Immuneering Corporation uses a bioinformatics platform to discover and develop targeted cancer treatments. The company combines IT and biotechnology. This chart shows a very high cost per employee, as the market values both the technology platform itself and the pipeline of potential drugs created using it.
%20of%20the%20company%20Immuneering%20Corporation%20(IMRX)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Immuneering-Corporation-IMRX&v=1772513886207 "Chart of market capitalization per employee (in thousands of dollars) of the company Immuneering Corporation (IMRX)")
Market capitalization per employee (in thousands of dollars) in the market segment - Oncology targeted therapy
Immuneering Corporation uses a bioinformatics platform to develop targeted therapies in oncology. This chart demonstrates the market's confidence in their technological approach. Their high market capitalization per employee compared to the sector suggests investors see significant potential in their platform, which can accelerate and reduce the cost of developing new drugs.
%20by%20market%20segment%20-%20Oncology%20targeted%20therapy&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Oncology-targeted-therapy&v=1772513886274 "Market capitalization per employee (in thousands of dollars) by market segment - Oncology targeted therapy")
Market capitalization per employee (in thousands of dollars) for the overall market
Immuneering Corporation uses an AI-powered platform for drug discovery. This demonstrates how modern technologies are accelerating value creation in the pharmaceutical industry. A small team of data scientists and biologists can analyze vast amounts of data, increasing the market value of their research.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772513886379 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Immuneering Corporation (IMRX)
Immuneering Corporation is a clinical-stage biotech company using an AI platform to develop cancer drugs. They are not profitable from sales. This chart shows the loss per employee. It's an indicator of the R&D budget "burn rate." It reflects the cost of a team of scientists and data scientists working to find new treatments.
%20Chart%20Immuneering%20Corporation%20(IMRX)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Immuneering-Corporation-IMRX&v=1772513886491 "Company Profit Per Employee (in thousands of dollars) Chart Immuneering Corporation (IMRX)")
Profit per employee (in thousands of dollars) in the market segment - Oncology targeted therapy
Immuneering Corporation is a biotech company using an artificial intelligence platform to discover new cancer drugs. They have no profit, only R&D expenses. Their business model emphasizes higher efficiency. This metric allows them to test this: is their R&D burn rate per employee lower than their competitors'?
%20in%20the%20market%20segment%20-%20Oncology%20targeted%20therapy&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Oncology-targeted-therapy&v=1772513886621 "Chart of profit per employee (in thousands of dollars) in the market segment - Oncology targeted therapy")
Profit per employee (in thousands of dollars) for the market as a whole
Immuneering Corporation uses AI for drug discovery and development. It's a hybrid of biotech and IT. They incur double costs: wet labs (biologists) and dry labs (data scientists). This chart shows whether their AI platform delivers real efficiencies, enabling faster target discovery and reduced R&D staff costs compared to traditional approaches.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772513886656 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Immuneering Corporation (IMRX)
Immuneering Corporation uses an AI-based platform to develop oncology drugs. This timeline is typical for early-stage biotech. The lack of revenue per employee means the company is in the research and development phase, building a pipeline of potential drugs.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Immuneering-Corporation-IMRX&v=1772513886686 "Sales chart per company employee Immuneering Corporation (IMRX)")
Sales per employee in the market segment - Oncology targeted therapy
Immuneering (IMRX) is a biotech company using an AI platform to map disease signaling pathways and develop targeted therapies, primarily in oncology. This chart shows how much revenue (from partnerships) each employee generates. It's an indicator of the productivity of their AI-based R&D platform compared to other biotech companies.
Sales per employee for the market as a whole
Immuneering Corporation is a biopharmaceutical company using an AI-based platform to develop targeted therapies for oncology. It is an early-stage R&D company and has no commercial revenue from drug sales. This metric is not yet informative, but it will eventually reveal whether their AI platform can create successful drugs with a small team.
Short shares by company, segment and market as a whole
Shares shorted by company Immuneering Corporation (IMRX)
Immuneering Corporation is a biotech company using AI to develop cancer drugs. This chart shows bearish bets. Bears are skeptical of its platform, expecting its candidates to fail in early clinical trials, which is typical for high-risk oncology startups.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Immuneering-Corporation-IMRX&v=1772513886911 "Short Shares Chart for the Company Immuneering Corporation (IMRX)")
Shares shorted by market segment - Oncology targeted therapy
Immuneering is a biotech company using AI to discover new targeted cancer drugs. This chart shows bearish sentiment. "Shorts" here are bets that their AI platform is ineffective or that their candidates will fail early clinical trials.
Shares shorted by the overall market
Immuneering Corporation uses AI to develop targeted therapies for oncology. This is high-tech biotech, where the stakes are high. This chart measures the overall level of fear. When investors are panicking about risks, the shares of these essentially "venture capital" companies can be the first to fall, regardless of their scientific potential.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Immuneering Corporation (IMRX)
Immuneering Corporation is a clinical-stage biotech. Its shares are extremely sensitive to trial news. This chart can surge above 70 on positive R&D data. Oversold territory (<30) often reflects research setbacks, funding concerns, or general risk aversion.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Immuneering-Corporation-IMRX&v=1772513887211 "RSI 14 indicator chart for the company's stock Immuneering Corporation (IMRX)")
RSI 14 Market Segment - Oncology targeted therapy
Immuneering (IMRX) is an "AI biotech." They use an *AI platform* to *find* new "attack points" (targets) for targeted cancer therapy. The RSI_14_Seg for "Oncology" (biotech) shows the overall sentiment. The chart helps us understand: is IMRX's volatility a function of their AI platform or general "hype"?
RSI 14 for the overall market
Immuneering (IMRX) is a biotech company. Like everything in its sector, it's critically dependent on this chart. Market euphoria is an easy way to raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast IMRX (Immuneering Corporation)
Immuneering (IMRX) uses its bioinformatics platform to discover new targeted cancer drugs. This chart shows the average 12-month forecast. It reflects analysts' speculative assessment of the potential of this AI platform and early clinical trial data.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-IMRX-Immuneering-Corporation&v=1772513887423 "A chart showing analyst consensus forecasts for the expected stock price. IMRX (Immuneering Corporation)")
The difference between the consensus estimate and the actual stock price IMRX (Immuneering Corporation)
Immuneering is an early-stage clinical-stage biotech company. They use their computational biology (AI) platform to discover new cancer targets (specifically, those targeting RAS mutations). This chart reflects analysts' speculative expectations for their R&D platform and data from their earliest clinical trials.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-IMRX-Immuneering-Corporation&v=1772513887447 "A chart showing the difference between the consensus forecast and the actual stock price. IMRX (Immuneering Corporation)")
Analyst consensus forecast for stock prices by market segment - Oncology targeted therapy
Immuneering is a biotech company that uses an AI platform to map disease signaling pathways and develop new targeted oncology drugs. This chart shows general expectations for the targeted oncology sector, reflecting whether experts believe AI can accelerate pharmaceutical R&D.
Analysts' consensus forecast for the overall market share price
Immuneering (IMRX) is a biopharmaceutical company using AI to understand disease biology. Their platform helps discover new targeted drugs for cancer treatment. This chart shows the overall risk appetite, reflecting the market's willingness to fund R&D platforms that promise to speed up and reduce the cost of drug development.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Immuneering Corporation
Immuneering is a clinical-stage biotech company. Their signature platform is a bioinformatics platform that uses bioinformatics to identify blind spots in cancer signaling pathways (MAPK). This graph is a pure R&D bet. It likely reflects the market's confidence in their computational platform and their early clinical data in treating complex tumors.
AKIMA Market Segment Index - Oncology targeted therapy
Immuneering (IMRX) is a clinical-stage AI biotech company using its AI-powered R&D platform to discover targeted drugs for cancer treatments (primarily targeting RAS/MAPK mutations). This summary metric measures R&D. The graph shows the segment average. This benchmark: how does this AI platform (IMRX) differentiate itself from the average pharma company?
The AKIM Index for the overall market
Immuneering is a biotech company developing universal cancer drugs targeting mutations in the MAPK/RAS pathway. It uses bioinformatics. This chart, which reflects the market average, provides a macro backdrop. It helps assess how this early-clinical research story compares to general economic trends and risk appetite.
